News stories about Flexion Therapeutics (NASDAQ:FLXN) have trended somewhat positive recently, AlphaOne Sentiment Analysis reports. The research group, a division of Accern, identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flexion Therapeutics earned a coverage optimism score of 0.07 on AlphaOne’s scale. AlphaOne also gave media headlines about the specialty pharmaceutical company an impact score of 85 out of 100, meaning that recent media coverage is very likely to have an effect on the company’s share price in the next several days.
FLXN has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 price objective on shares of Flexion Therapeutics in a report on Saturday, March 11th. Cantor Fitzgerald set a $37.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a report on Thursday, February 23rd. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 21st. BMO Capital Markets reissued a “positive” rating and set a $33.00 price target on shares of Flexion Therapeutics in a report on Tuesday, February 7th. Finally, Raymond James Financial, Inc. initiated coverage on Flexion Therapeutics in a report on Thursday, December 22nd. They set a “strong-buy” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $28.68.
Shares of Flexion Therapeutics (NASDAQ:FLXN) traded down 2.19% during midday trading on Friday, reaching $26.37. 322,925 shares of the company were exchanged. Flexion Therapeutics has a 52-week low of $8.16 and a 52-week high of $29.41. The stock’s market capitalization is $836.75 million. The company’s 50-day moving average price is $24.28 and its 200 day moving average price is $20.44.
Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.07. On average, equities analysts predict that Flexion Therapeutics will post ($3.50) earnings per share for the current year.
In related news, CFO Frederick W. Driscoll sold 3,000 shares of the stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $23.00, for a total transaction of $69,000.00. Following the completion of the sale, the chief financial officer now directly owns 10,777 shares of the company’s stock, valued at $247,871. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Neil Bodick sold 5,000 shares of the stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $28.23, for a total transaction of $141,150.00. Following the sale, the insider now directly owns 46,137 shares of the company’s stock, valued at $1,302,447.51. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,000 shares of company stock valued at $407,950. Company insiders own 18.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/04/21/flexion-therapeutics-flxn-earns-daily-news-sentiment-score-of-0-07.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.